Cardiovascular biomarkers in patients with psoriasis

Psoriasis is a systemic inflammatory disease of the skin with associated comorbidity. Severe forms of psoriasis are associated with increased mortality, which might be due to cardiovascular (CV) comorbidity. In this study, we investigated in 79 patients with psoriasis compared to 80 healthy volunteers different biomarkers that play a role in vascular disease and inflammation, such as C‐reactive protein (CRP), human soluble CD40 ligand (sCD40L), oxidized low‐density lipoprotein (ox‐LDL), human matrix Gla protein (MGP) and fetuin‐A. Our results showed that CRP (P < 0.0001), sCD40L (P < 0.0001) and MGP (P < 0.0001) were increased in the patient cohort. Fetuin‐A showed decreased serum levels in patients with psoriasis (P < 0.0001), whereas ox‐LDL did not show any significant difference. In multivariate analyses controlling for sex, age and BMI, these findings were confirmed. Thus, CV biomarkers are altered in patients with psoriasis. If the decrease in fetuin‐A as well as the increase in sCD40L can be proven in further studies, these biomarkers may help to characterize a subgroup of patients who are at risk to develop CVD and/or monitor the effect of therapeutic antipsoriatic strategies on concomitant diseases. This knowledge may be useful in the management of high‐need patients with psoriasis.

[1]  F. Dekker,et al.  Association of serum fetuin-A levels with mortality in dialysis patients. , 2007, Kidney international.

[2]  Yin Tintut,et al.  Regulatory mechanisms in vascular calcification , 2010, Nature Reviews Cardiology.

[3]  J. Mehta,et al.  LOX-1, an Oxidized LDL Endothelial Receptor, Induces CD40/CD40L Signaling in Human Coronary Artery Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[4]  F. Castro-Giner,et al.  A CD40 and an NCOA5 gene polymorphism confer susceptibility to psoriasis in a Southern European population: a case-control study. , 2011, Human immunology.

[5]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[6]  C. Shanahan,et al.  Inflammation ushers in calcification: a cycle of damage and protection? , 2007, Circulation.

[7]  C. Jung,et al.  Associations of serum fetuin-A levels with insulin resistance and vascular complications in patients with type 2 diabetes , 2013, Diabetes & vascular disease research.

[8]  N. Tekin,et al.  Accumulation of Oxidized Low-Density Lipoprotein in Psoriatic Skin and Changes of Plasma Lipid Levels in Psoriatic Patients , 2006, Mediators of inflammation.

[9]  A. Bowcock,et al.  Association of Cardiovascular and Metabolic Disease Genes with Psoriasis , 2012, The Journal of investigative dermatology.

[10]  Michael J Blaha,et al.  High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? , 2013, Journal of the American College of Cardiology.

[11]  K. Reich,et al.  Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis , 2009, The British journal of dermatology.

[12]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[13]  Z. Massy,et al.  Inhibitors of vascular calcification as potential therapeutic targets. , 2011, Journal of nephrology.

[14]  Timur Shtatland,et al.  Osteogenesis Associates With Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo , 2007, Circulation.

[15]  Ghada S. Hassan,et al.  CD40 ligand: a neo-inflammatory molecule in vascular diseases. , 2012, Immunobiology.

[16]  Andrea B Troxel,et al.  The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.

[17]  M. Górska,et al.  Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients. , 2012, Folia histochemica et cytobiologica.

[18]  R. Scrivo,et al.  Biomarkers of Subclinical Atherosclerosis in Patients with Autoimmune Disorders , 2012, Mediators of inflammation.

[19]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[20]  M. Emoto,et al.  Fetuin-A: a multifunctional protein. , 2011, Recent patents on endocrine, metabolic & immune drug discovery.

[21]  L. Arends,et al.  Markers of systemic inflammation in psoriasis: a systematic review and meta‐analysis , 2013, The British journal of dermatology.

[22]  S. Möller,et al.  Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease , 2013, Experimental dermatology.

[23]  J. Mehta,et al.  Oxidized LDL, LOX-1 and Atherosclerosis , 2011, Cardiovascular Drugs and Therapy.

[24]  C. Stefanadis,et al.  The CD40/CD40 ligand system: linking inflammation with atherothrombosis. , 2009, Journal of the American College of Cardiology.

[25]  M. Weichenthal,et al.  Leptin, adiponectin, visfatin and retinol‐binding protein‐4 – mediators of comorbidities in patients with psoriasis? , 2012, Experimental dermatology.

[26]  B. Pamukcu,et al.  The CD40-CD40L system in cardiovascular disease , 2011, Annals of medicine.

[27]  V. Garg,et al.  Role of fetuin‐A in atherosclerosis associated with diabetic patients , 2012, The Journal of pharmacy and pharmacology.

[28]  G. Pamuk,et al.  Elevated platelet-monocyte complexes ın patıents wıth psorıatıc arthrıtıs , 2009, Platelets.

[29]  G. Pamuk,et al.  Increased platelet activation markers in rheumatoid arthritis: Are they related with subclinical atherosclerosis? , 2008, Platelets.